# GeneCraft

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genecraft

- Industry: Biotechnology
- Headquarters: Cheongju, South Korea
- Website: www.genecraft.co.kr
- Total disclosed funding: $7.6M
- Latest round: Series A (Jan 15, 2024)
- Investors on record: 3

## About

Based in Cheongju, South Korea, and founded in 2020, GeneCraft operates as a biotechnology company with research exchange centers conducting gene theraphy. In January 2024, the firm raised KRW 10 billion in series A funding led by investors Seoul Technology Holdings, Infobank, and Cosine Investment. The firm as of January 2024, has a clinical trial center in Hwasung Gyeonggi Provice and a research center in Republic of Korea and is led by its CEO, Suk Chul Bae.

The pre-clinical-stage biotech company offers gene therapy, for treatment outcomes of incurable diseases by leveraging the innate oncogene defense system. GeneCraft’s technical features include programs like RX001, a first-in-class treatment for Pan K-RAS mutated lung cancer. The firm employs the Ubi-AAV Platform to craft gene therapeutics, distinguishing abnormal K-RAS mutated cancer cells and selectively inducing their death.

## Funding rounds

- Series A, Jan 15, 2024, $7.6M — Cosine Investment, Seoul Technology Holdings, Infobank

## Investors

- Cosine Investment — Series A
- Seoul Technology Holdings (https://capitalatlas.ai/funds/seoul-technology-holdings) — Series A
- Infobank (https://capitalatlas.ai/funds/infobank) — Series A